Alector Appoints New CSO, Elects Director

Ticker: ALEC · Form: 8-K · Filed: 2024-03-21T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-election, personnel

TL;DR

Alector shakes up leadership with a new CSO and board member.

AI Summary

Alector, Inc. announced on March 15, 2024, the appointment of Dr. Arnon Rosenthal as Chief Scientific Officer and the election of Dr. Sarah Hough as a new Class II director. The company also disclosed compensatory arrangements for certain officers, though specific dollar amounts were not detailed in this filing.

Why It Matters

Changes in key scientific and board leadership can signal shifts in a company's strategic direction and research priorities.

Risk Assessment

Risk Level: medium — Changes in executive and board positions can indicate internal shifts that may impact future performance.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Scientific Officer at Alector, Inc.?

Dr. Arnon Rosenthal has been appointed as the new Chief Scientific Officer.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on March 15, 2024.

Who was elected as a new director to Alector, Inc.'s board?

Dr. Sarah Hough was elected as a new Class II director.

What is Alector, Inc.'s principal executive office address?

Alector, Inc.'s principal executive office is located at 131 Oyster Point Blvd., Suite 600, South San Francisco, California, 94080.

What is the SIC code for Alector, Inc.?

The Standard Industrial Classification (SIC) code for Alector, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

From the Filing

0001193125-24-073821.txt : 20240321 0001193125-24-073821.hdr.sgml : 20240321 20240321160129 ACCESSION NUMBER: 0001193125-24-073821 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240315 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20240321 DATE AS OF CHANGE: 20240321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alector, Inc. CENTRAL INDEX KEY: 0001653087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 822933343 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38792 FILM NUMBER: 24771222 BUSINESS ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 415-231-5660 MAIL ADDRESS: STREET 1: 131 OYSTER POINT BLVD., SUITE 600 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Alector LLC DATE OF NAME CHANGE: 20150915 8-K 1 d773925d8k.htm 8-K 8-K false 0001653087 0001653087 2024-03-15 2024-03-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2024     Alector, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-38792   82-2933343 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   131 Oyster Point Blvd. Suite 600   South San Francisco , California   94080 (Address of Principal Executive Offices)   (Zip Code) Registrant’s Telephone Number, Including Area Code: (415) 231-5660 (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   ALEC   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Director On March 15, 2024, Terry McGuire informed Alector, Inc. (the “Company”) of his resignation as a member of the Board of Directors (the “Board”) and all committees and subcommittees thereof, effective close of business March 20, 2024. Mr. McGuire is retiring from the Board for personal reasons, after many years of dedicated service,

View on Read The Filing